Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (23)	7/15/1998 1:28:00 AM
From: Larry Liebman	Read Replies (1) \| Respond to of 1475

O.K. Richard...What am I missing? There are 8.5 million shares out. With BTRN at $3 you're talking about a market cap of $25.5 million. As of 3/31/98 cash and equivalents were at $27 million. In the investor packet they discuss such items as: (a) the Novartis xenotransplantation agreement with an implied value of $36 million (b) the breakout of MEDI-507 into autoimmune diseases like psoriasis- and the partnership with MedImmune, and (c) a 30% equity stake in an Australian firm known as Stem Cell Sciences, which has entered into an agreeement with Genentech. This ignores the primary work of BTRN in organ rejection, with products in clinical trials. I have to agree with your assessment, BTRN looks compelling at these levels.